|1.||June, Carl H: 29 articles (09/2015 - 03/2008)|
|2.||Dotti, Gianpietro: 27 articles (11/2015 - 06/2007)|
|3.||Rosenberg, Steven A: 23 articles (07/2015 - 12/2007)|
|4.||Abken, Hinrich: 20 articles (12/2015 - 02/2011)|
|5.||Rooney, Cliona M: 20 articles (06/2015 - 06/2007)|
|6.||Cooper, Laurence J N: 19 articles (07/2015 - 07/2007)|
|7.||Jensen, Michael C: 17 articles (09/2015 - 04/2007)|
|8.||Grupp, Stephan A: 16 articles (12/2015 - 08/2011)|
|9.||Morgan, Richard A: 16 articles (07/2015 - 09/2009)|
|10.||Savoldo, Barbara: 15 articles (07/2015 - 06/2007)|
03/04/2015 - "Chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) provide a potent antitumor response and have become a promising treatment option for cancer. "
07/01/2013 - "Adoptive immunotherapy using T lymphocytes genetically modified to express a chimeric antigen receptor (CAR-T) holds considerable promise for the treatment of cancer. "
09/01/2014 - "The use of human T lymphocytes genetically modified to express chimeric antigen receptors on their surfaces has emerged as a promising treatment strategy for malignant tumors. "
08/19/2015 - "Chimeric antigen receptors (CARs) have shown great promise for the immunological treatment of cancer. "
01/01/2015 - "T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer therapy, particularly in the treatment of B-cell malignancies. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
05/01/2014 - "Cytotoxic T lymphocytes modified with chimeric antigen receptors (CARs) for adoptive immunotherapy of hematologic malignancies are effective in pre-clinical models, and this efficacy has translated to success in several clinical trials. "
12/01/2011 - "Cytotoxic T lymphocytes (CTLs) modified with chimeric antigen receptors (CARs) for adoptive immunotherapy of hematologic malignancies are effective in preclinical models and are being tested in several clinical trials. "
11/01/2014 - "Chimeric antigen receptor (CAR) therapy has begun to demonstrate success as a novel treatment modality for hematologic malignancies. "
02/01/2013 - "Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. "
10/01/2014 - "Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has shown promising antitumor activity in early phase clinical studies, especially for hematological malignancies. "
01/01/2015 - "This is impressively demonstrated by redirecting T cells with a chimeric antigen receptor (CAR) towards CD19, inducing complete and lasting remission of leukemia in more than two-thirds of patients in early phase trials. "
11/01/2005 - "We analyzed 140 remission samples from 91 patients using both competitive PCR amplification of antigen-receptor genes and four-color FC identification of leukemia immunophenotype. "
01/01/2013 - "Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed spectacular efficacy in the treatment of leukemia in recent early phase trials. "
10/01/1990 - "During the past decade, our knowledge concerning immunologic development and function has expanded rapidly as a result of the interplay between fundamental studies of antigen receptors and lymphokine molecules and the genes encoding them and studies of patients with leukemias, autoimmune disorders, and immunodeficiency diseases. "
11/01/2015 - "The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia. "
|4.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/18/2013 - "Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). "
01/01/2003 - "B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor."
12/01/1996 - "Functional studies revealed that two groups of B chronic lymphocytic leukemia (B-CLL) can be distinguished based on their capacity to mount a proliferative response following B-cell antigen receptor (BCR) cross-linking. "
09/02/2015 - "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia."
02/01/2015 - "On the basis of somatic hypermutation status of their B-cell antigen receptor (BCR) genes, chronic lymphocytic leukemia (CLL) patients can be divided into unmutated CLL (U-CLL) or mutated CLL (M-CLL). "
|5.||Melanoma (Melanoma, Malignant)
04/01/2015 - "DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma."
01/01/2014 - "Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor."
07/15/2015 - "This study was designed to engineer a chimeric antigen receptor (CAR) on T-cell surface, such that they target tumors in advanced stages of melanoma. "
10/15/2007 - "Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth."
05/15/2010 - "The aims of this study are to compare antitumor activities of two generations of GD3-specific chimeric antigen receptors (CAR) in human primary T lymphocytes in vitro and to evaluate the antitumor efficacy of using a combination of systemic infusion of interleukin-2 (IL2) and designer T cells to eradicate subcutaneous established GD3+ melanoma in nude mice. "
|2.||T-Cell Antigen Receptors (T-Cell Receptor)
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||epidermal growth factor receptor VIII
|10.||Interleukin-15 (Interleukin 15)
|2.||Tissue Therapy (Cell Therapy)
|3.||Drug Therapy (Chemotherapy)